Pfizer's Preemption Defense Explained: Why the FDA Label Change Blew It Apart

For years, Pfizer's central defense in the Depo-Provera meningioma litigation rested on a single legal pillar: federal preemption. The argument, stated plainly, was this — "We tried to warn women. The FDA said no. Federal law prevented us from acting unilaterally. Therefore, you cannot hold us liable under state law for failing to warn."

Then, on December 17, 2025, the FDA approved a label change to Depo-Provera's prescribing information that explicitly acknowledged meningioma brain tumors had been reported following repeated administrations of the drug. With that regulatory action, the FDA did the very thing Pfizer had claimed was impossible.

The legal implications for 3,769 pending cases in MDL 3140 — the federal multi-district litigation before Judge M. Casey Rodgers in the Northern District of Florida — are significant. Understanding what preemption is, why Pfizer relied on it, and why the December 2025 label change undermined it is essential for anyone with a pending or potential Depo-Provera case.

1. What Federal Preemption Means in Drug Lawsuits

The Supremacy Clause of the U.S. Constitution establishes that federal law is "the supreme Law of the Land." When federal law and state law conflict, federal law wins — states are preempted from enforcing conflicting rules. In pharmaceutical litigation, this principle has become one of the drug industry's most powerful legal shields.

For branded prescription drugs, preemption typically arises in two forms:

The landmark Supreme Court case for branded drug preemption is Wyeth v. Levine (2009). In that case, the Court held that FDA approval of a drug label does NOT automatically preempt state failure-to-warn claims. Brand-name manufacturers, unlike generic manufacturers, have a continuing duty under FDA's "Changes Being Effected" (CBE) regulation to update their labels when new safety information emerges — without waiting for prior FDA approval.

2. Pfizer's "FDA Blocked Us" Defense — How It Was Built

In MDL 3140, Pfizer's preemption argument was carefully constructed around a specific regulatory narrative. The argument went roughly as follows:

This framework allowed Pfizer to simultaneously acknowledge that it knew about meningioma concerns while escaping liability for not warning patients. The defense depended on two factual pillars:

• looks_one

  That Pfizer actually submitted label change requests to the FDA — establishing that it tried to add a warning and was rebuffed, rather than simply choosing not to act

• looks_two

  That the FDA affirmatively rejected those requests — creating the "impossibility" required for the defense, rather than merely declining to require a warning of its own initiative

Plaintiffs challenged both pillars. They argued that the discovery record — including more than 8,000 previously privileged documents — shows that Pfizer did not submit robust, complete Supplemental New Drug Applications that fully disclosed the meningioma risk evidence. They also argue that under the CBE regulation, Pfizer had the right and duty to add the warning regardless.

3. February 2024: The FDA Rejection Pfizer Cited

In February 2024, the FDA responded to a label change submission from Pfizer and — according to Pfizer's account of the regulatory exchange — initially declined to require the meningioma warning language that Pfizer had proposed. Pfizer has pointed to this exchange as evidence of the FDA affirmatively blocking the labeling change, which is the linchpin of its impossibility preemption argument.

Plaintiff attorneys have disputed Pfizer's characterization of the February 2024 exchange. Key questions in the litigation include whether Pfizer submitted complete scientific evidence with its label change request, what language was specifically proposed and rejected, and whether the rejection was a definitive "no" or a request for additional data. These questions are being litigated in discovery, and the answers will significantly affect how courts evaluate the preemption argument.

4. December 2025: How the Label Change Collapsed the Defense

On December 17, 2025, the FDA approved supplemental New Drug Application NDA 020246s074 — updating Depo-Provera's prescribing information to acknowledge the meningioma risk. This was the first meningioma warning on any FDA-approved contraceptive label in the United States.

The legal significance for preemption was immediate and dramatic. Here is why:

5. Judge Rodgers' Supplemental Briefing Order

Judge M. Casey Rodgers, who is presiding over MDL 3140 in the Northern District of Florida, recognized the significance of the December 2025 FDA label change for the pending preemption motions. In response, she ordered supplemental briefing from both sides to address how the label change affects the preemption analysis.

This procedural step was significant for several reasons:

• check_circle

  It signaled that the court viewed the December 2025 label change as legally material to the preemption analysis — not a minor development the court could ignore

• check_circle

  It gave plaintiffs the opportunity to formally argue that the label change eliminated or severely weakened any basis for preemption

• check_circle

  It gave Pfizer the opportunity to argue its narrowed, fallback preemption position — that even if full preemption no longer applies, partial preemption for pre-2024 injuries should still be recognized

• check_circle

  It delayed final resolution of the preemption question — but that delay works in plaintiffs' favor, as the litigation continues to grow and the June 2026 Daubert hearing advances on schedule

The court's ruling on the supplemental preemption briefing is expected before or alongside the June 2026 Daubert hearing. That ruling will be one of the most consequential pre-trial decisions in MDL 3140.

6. Pfizer's Fallback: The Pre-2024 Time-Cut Argument

Recognizing that December 2025 damaged its full preemption defense, Pfizer has pivoted to a narrower, temporal version of the argument. The fallback position, in essence, is: "Even if preemption no longer applies going forward, it still applies to injuries that occurred before July 2024 — when the FDA first formally acknowledged the meningioma risk."

The logic of the fallback runs as follows:

The significance of this fallback cannot be understated. MDL 3140 includes thousands of plaintiffs whose Depo-Provera use and diagnoses span from the 1990s through the early 2020s. If Pfizer succeeds on this temporal preemption argument, a large portion of the MDL could be subject to motions for summary judgment on failure-to-warn claims.

7. Why Plaintiff Attorneys Say Even the Fallback Fails

Plaintiff attorneys in MDL 3140 have contested Pfizer's temporal preemption argument on multiple grounds. Their core counterarguments are:

8. What This Means for Settlement Negotiations

Settlement negotiations in mass tort MDLs are driven by defendants' assessment of their litigation risk. The strength of a preemption defense directly affects how much Pfizer is willing to pay — and how quickly. Here is the current settlement picture given the preemption developments:

Mass tort defense strategy often involves using legal defenses like preemption as leverage in settlement negotiations — even defenses that are unlikely to fully succeed at trial. The December 2025 label change substantially reduced that leverage. Attorney projections as of mid-2026 range from $275,000 to $1.5 million or more per case for significant injuries, with past meningioma jury verdicts averaging over $3 million.

9. What Individual Plaintiffs Should Know

If you or a family member used Depo-Provera for one year or more and developed a meningioma brain tumor, here is what the preemption developments mean for your specific situation: